Sirtex SIR-spheres fail to meet primary endpoint in head-to-head trial

Sirtex Medical (ASX:SRX) shares are down slightly today after its radioactive microspheres failed to meet the primary endpoint in a liver cancer trial.

The company’s SIR-Spheres Y-90 resin microspheres did not improve survival in patients with advanced hepatocellular carcinoma compared to a group treated with the current standard of care, sorafenib.

Get the full story at our sister site, Drug Delivery Business News.

The post Sirtex SIR-spheres fail to meet primary endpoint in head-to-head trial appeared first on MassDevice.

from MassDevice http://ift.tt/2qTqkSR